This HTML5 document contains 57 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/mesh/concept/
n9http://bio2rdf.org/drugbank:
n15http://linked.opendata.cz/resource/drugbank/drug/DB01613/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/drug/DB01613/identifier/pharmgkb/
n5http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n7http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://linked.opendata.cz/resource/atc/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01613/identifier/drugbank/
n12http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01613
rdf:type
n3:Drug
n3:description
A vasodilator with general properties similar to nitroglycerin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1020)
n3:group
approved
n3:indication
For the prevention of angina.
owl:sameAs
n5:DB01613 n9:DB01613
dcterms:title
Erythrityl Tetranitrate
adms:identifier
n11:PA164746528 n15:60072 n16:DB01613
n3:mechanismOfAction
Similar to other nitrites and organic nitrates, erythrityl tetranitrate is converted to an active intermediate compound which activates the enzyme guanylate cyclase. This stimulates the synthesis of cyclic guanosine 3',5'-monophosphate (cGMP) which then activates a series of protein kinase-dependent phosphorylations in the smooth muscle cells, eventually resulting in the dephosphorylation of the myosin light chain of the smooth muscle fiber. The subsequent release of calcium ions results in the relaxation of the smooth muscle cells and vasodilation.
n3:synonym
Tetranitrol Eritrityli tetranitras (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate Meso-erythritol tetranitrate Erythrol tetranitrate Tetranitrin Eritrityl tetranitrate Tetranitrato de eritritilo Erythritol tetranitrate 1,2,3,4-Butanetetralyl tetranitrate ETN Tetranitrate d'eritrityle
n3:toxicity
Symptoms of overdose include increased intracranial pressure, with any or all of persistent throbbing headache, confusion, and moderate fever; Vertigo; Palpitations; Visual disturbances; Nausea and vomiting (possibly with colic and even bloody diarrhea); Syncope (especially in the upright posture); Air hunger and dyspnea, later followed by reduced ventilatory effort; Diaphoresis, with the skin either flushed or cold and clammy; Heart block and bradycardia; Paralysis; Coma; Seizures; Death.
n3:foodInteraction
Avoid alcohol. Take on empty stomach: 1 hour before or 2 hours after meals.
n7:hasConcept
n8:M0007686
n3:IUPAC-Name
n6:271B5C48-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B5C4E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B5C4D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B5C4A-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B5C4B-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B5C4C-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B5C46-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B5C44-363D-11E5-9242-09173F13E4C5 n6:271B5C47-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B5C45-363D-11E5-9242-09173F13E4C5
n12:hasATCCode
n13:C01DA13
n3:H-Bond-Acceptor-Count
n6:271B5C54-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B5C55-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B5C4F-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B5C50-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B5C52-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B5C51-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B5C53-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
7297-25-8
n3:category
n3:Bioavailability
n6:271B5C59-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B5C5B-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B5C5C-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n6:271B5C5D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B5C58-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B5C57-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B5C5A-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B5C49-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B5C56-363D-11E5-9242-09173F13E4C5